“…This component of the value of early screening for and identification of AD is important for patients and payers to understand and consider when deciding whether to participate in or offer coverage for early testing, respectively. Patients will also want to consider other aspects of the utility (or disutility) of early screening and identification of AD, such as the potentially negative psychological effects of receiving bad health news, the potential for discrimination based on test results, and, on the positive side, the value of reduced uncertainty for future planning (Hall, Viney, & Haas, 1998, Lliffe & Manthorpe, 2004, Billings et al, 1992, Hsu & Willis, 2013, Grosse, Wordswort, & Payne, 2008, Shin et al, 2019.…”